NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 12:06
Last Report Issued 02/13/2013 10:34

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1804SP
Patient ID 1804SP
Chain 13000596
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 13000596

Received 01/30/2013 12:25

Sample ID 13000596-001
Matrix Serum or Plasma
Patient Name 1804SP
Patient ID 1804SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
1804SP Diuretics Panel, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Chlorothiazide	None Detected	ng/mL	25	
Synonym(s): Diuril®				
Peak plasma levels following a single 500 mg oral dose of chlorothiazide were 400 - 900 ng/mL at approximately 1 to 2 hours post dose.				
Hydrochlorothiazide	None Detected	ng/mL	25	
Synonym(s): Microzide®				
Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients:				
25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose				
75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.				
Furosemide	None Detected	ng/mL	100	
Synonym(s): Lasix®; Frusemide				

Results for sample 13000596-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 13000596-001
Matrix Serum or Plasma
Patient Name 1804SP
Patient ID 1804SP

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Mean peak serum levels of 2300 +/- 500 ng/mL were obtained approximately 1 hour after a single oral dose of 80 mg furosemide in fasting subjects.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.